Table 1.

Randomized clinical trials in adults with sickle cell disease.

Clinical TrialOutcome
* Non FDA-approved 
Multicenter Study of Hydroxyurea in Sickle Cell Anemia15  Hydroxyurea reduces the frequency of painful episodes, acute chest syndrome, transfusions, hospitalizations 
Preoperative Transfusion in Sickle Cell Disease28  Simple blood transfusion to increase the Hb level to 10 g/dL is as effective as exchange transfusion to reduce Hb S to 30% 
Prophylactic Transfusion in Pregnancy16  Prophylactic blood transfusion to increase the Hb level to 10 g/dL compared to transfusion for Hb < 6 g/dL or for emergent indications did not improve obstetrical or perinatal outcomes but reduced the incidence of painful episodes 
Captopril for Albuminuria in Sickle Cell Anemia33  Captopril reduces albuminuria in normotensive patients 
Poloxamer 188* for Treatment of Acute Vaso-occlusive Crisis12  Poloxamer 188 reduces the duration of acute painful episodes 
Clinical TrialOutcome
* Non FDA-approved 
Multicenter Study of Hydroxyurea in Sickle Cell Anemia15  Hydroxyurea reduces the frequency of painful episodes, acute chest syndrome, transfusions, hospitalizations 
Preoperative Transfusion in Sickle Cell Disease28  Simple blood transfusion to increase the Hb level to 10 g/dL is as effective as exchange transfusion to reduce Hb S to 30% 
Prophylactic Transfusion in Pregnancy16  Prophylactic blood transfusion to increase the Hb level to 10 g/dL compared to transfusion for Hb < 6 g/dL or for emergent indications did not improve obstetrical or perinatal outcomes but reduced the incidence of painful episodes 
Captopril for Albuminuria in Sickle Cell Anemia33  Captopril reduces albuminuria in normotensive patients 
Poloxamer 188* for Treatment of Acute Vaso-occlusive Crisis12  Poloxamer 188 reduces the duration of acute painful episodes 
Close Modal

or Create an Account

Close Modal
Close Modal